AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
A phase 1/2 trial of Ivonescimab, Cadonilimab, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Akeso, active and no longer recruiting.
Overview
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer is a phase 1/2 interventional study registered as NCT06646055 by Akeso, with 110 participants planned, started 2025-01-21 and due to reach its primary completion in 2026-12-30. Interventions recorded: AK112, Cadonilimab, nab-paclitaxel, gemcitabine, AK112, Cadonilimab, nab-paclitaxel, gemcitabine, AK112, Cadonilimab, nab-paclitaxel, gemcitabine, AK112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine. Conditions listed: Metastatic Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Shares Ivonescimab, Akeso, Gemcitabine, Pancreatic ductal adenocarcinoma.
- TrialAn Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Shares Cadonilimab, Ivonescimab, Akeso.
- TrialA Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Shares Cadonilimab, Akeso, Gemcitabine, Pancreatic ductal adenocarcinoma.
- TrialAK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Shares Ivonescimab, Akeso, Paclitaxel / nab-paclitaxel.
- TrialAK104 for Recurrent or Metastatic Vulvar Cancer
Shares Cadonilimab, Akeso, Paclitaxel / nab-paclitaxel.
- TrialAK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Shares Cadonilimab, Ivonescimab, Akeso, Paclitaxel / nab-paclitaxel.
- TrialA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Shares Cadonilimab, Ivonescimab, Akeso.
- TrialA Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Shares Cadonilimab, Ivonescimab, Akeso.